Manulife (MFC): The Turnaround Is Real. The Question Is Whether the Price Still Reflects Value.

Manulife Financial delivered a second-quarter 2026 that checked nearly every box on the turnaround playbook. Core EPS rose 16% year-over-year to C$1.09. APE sales — the annualized premium equivalent that measures new insurance business volume — surged 21%. Core return on equity expanded 130 basis points to 16.3%. And on the day the results landed, management announced a third long-term care reinsurance deal that will reduce cumulative LTC risk by 24%.

The operational story is no longer in question. The question that matters for investors now is valuation: after the stock has climbed nearly 47% over the trailing twelve months, does the price still reflect a gap with underlying value, or has the market moved past the point where MFC serves as an attractive retirement-quality holding?

The Growth Engine

Asia did the heavy lifting. Core earnings in the segment rose 21% to $616 million, driven by sales growth across Hong Kong, Singapore, and Japan. Year-to-date APE sales in Asia grew 15%, with new business CSM (the deferred profit pool under IFRS 17 that tracks the present value of future margins on new business) up 16%. The organic CSM balance — the cumulative profit runway sitting on the books — is growing at a 10% annualized rate.

The United States showed the sharpest earnings acceleration, up 55%, fueled by improved claims experience in life and long-term care and lower expected credit loss charges. APE sales rose 12%, though new business CSM declined 1% due to product mix. Growth is there, but margin quality softened.

Canada is the weak link. Core earnings fell 10% to C$379 million despite APE sales rising 23%. Unfavorable claims experience and higher group insurance expenses overwhelmed actuarial assumption benefits and an expected credit loss provision release. Canada represents a smaller share of Manulife's global earnings, but its profitability reversal after months of improvement is a data point worth monitoring.

Global wealth and asset management grew average assets under management 15% to $1.162 trillion, with core EBITDA margins expanding 110 basis points to 31.2%. The flow story is mixed: $4.9 billion in retirement outflows (versus $2.0 billion in inflows a year ago) and $1.4 billion in retail outflows were more than offset by $6.7 billion in institutional inflows, largely in fixed income, money market, and private credit mandates.

The implication: Manulife's growth is broad-based but not uniform. Asia is the compounding engine, the U.S. is recovering, Canada is a drag, and Global WAM is margin-accretive despite flow turbulence. That mix supports the 16% core EPS growth, but the next step — sustaining double-digit growth from a larger base — is harder.

The LTC Risk Resolution

The $3.2 billion long-term care reinsurance transaction with Munich Re, announced alongside Q2 results, is the most underrated element of this quarter. This is Manulife's third LTC deal in under three years and the first structured as a standalone LTC block. The 80% quota share transfers full biometric risk on a portfolio with $3.2 billion in IFRS reserves, at a modest 5% negative cede — meaning Manulife is paying slightly more in ceded premiums than it receives back in ceded benefits, which validates its own reserve assumptions.

Cumulatively, the three deals (including prior transactions with Global Atlantic and RGA) reduce LTC morbidity sensitivity by 24%. The annual earnings hit is approximately $30 million in the first year, declining over time, and the transaction is largely capital-neutral.

This matters because LTC risk has hung over Manulife's balance sheet as an overhang for years. Each deal at reasonable pricing tells the market that management's reserve assumptions are credible, not inflated to hide future shortfalls. The 24% cumulative reduction is structural de-risking, not accounting maneuvering. It's the kind of balance-sheet cleanup that doesn't show up on a headline growth rate but changes the risk profile of the earnings stream.

The Valuation Check

Here's where the story gets complicated. MFC trades at C$44.32 on a trailing P/E of 16.5x, with a forward P/E of 23.7x. That forward multiple implies the market expects substantial earnings growth to continue — the kind of growth Manulife delivered in 2025 and early 2026, but not necessarily what the base case supports going forward.

The stock sits at 1.9x common book value (C$27.48 per share) and roughly 1.08x adjusted book value (C$41.12 per share). Adjusted book strips out intangible assets and other non-operating items, giving a cleaner measure of the capital that actually earns a return. Trading just above adjusted book means the market is assigning a modest premium to Manulife's earning power above its capital base.

For comparison, Canadian banking peers trade at notable premiums to book — Royal Bank at 2.8x, BMO at 2.0x, BNS at 1.7x — but those are deposit-taking institutions with different risk profiles and capital structures. Manulife's 16.5x trailing P/E sits in line with BNS and below BMO and RBC, which is reasonable given its Asia exposure and insurance business model.

The dividend yield of 3.1%, with 11 consecutive years of increases and a payout ratio of 51%, is well supported by earnings growth. The stock is up 22% year-to-date and nearly 47% over the trailing twelve months, having more than recovered from its late-2024 lows near C$29.70.

The PEG ratio of 0.76 — trailing P/E divided by the earnings growth rate — looks attractive in isolation. But PEG ratios can be misleading when growth is cyclical or when the forward multiple already embeds aggressive expectations. The 23.7x forward P/E is the tell: it's the kind of multiple that assumes 15-20% earnings growth persists. If growth normalizes to high-single digits, that multiple compresses.

What Sustains the Case

The arguments that still support ownership are concrete. The CSM balance — C$27.3 billion post-tax, net of non-controlling interests — represents a multi-year profit runway from already-sold business. At 10% annualized organic growth, that balance compounds independently of new sales. The expense efficiency ratio improved 100 basis points to 44.5%, showing that the cost structure is scaling below revenue growth. The LICAT ratio (Canada's regulatory capital test for life insurers) sits at 136%, providing cushion above the 100% minimum. Financial leverage declined to 22.2% from 23.6%, meaning the balance sheet is getting stronger, not more stressed.

The LTC reinsurance program removes one of the few genuine overhangs on the valuation. The Asia growth story — while facing competitive pressure in Hong Kong and regulatory transitions like the eMPF shift — has demonstrated pricing power and distribution scale that are difficult to replicate. A 36.3% NBV margin (new business value as a percentage of APE) in Asia is durable for a business of this scale.

What Would Break It

Canada's claims experience is the most immediate risk. Group insurance losses and elevated claim frequency are not new in the sector, but if they persist, they will compress core ROE and offset growth elsewhere. The U.S. segment's declining new business CSM, even alongside strong earnings recovery, suggests product mix is shifting toward lower-margin business. And the Global WAM retirement outflows of $4.9 billion — a reversal from $2.0 billion in inflows a year ago — could reflect structural demographic pressure rather than a quarterly blip.

More fundamentally, the 23.7x forward P/E leaves little margin for error. If core EPS growth slows from 16% to high single digits, that multiple needs to contract, which means the stock price stops appreciating even if earnings continue to grow. That's not a bear case; it's a normalization case. And for a retirement portfolio, the question is never "will earnings grow?" but "will total returns justify the capital commitment?"

The Verdict

Manulife is no longer a cigar butt. It's a company that has executed a genuine operational turnaround and is now priced at the premium that turnaround execution commands. The growth is real, the balance sheet is de-risking, and the dividend is safe. But the valuation gap that made MFC an attractive entry in 2025 has largely closed.

Rating: Hold

For existing holders, the thesis remains intact. The CSM compounding, LTC risk reduction, and dividend growth provide a foundation for solid total returns. There's no reason to sell into strength.

For new capital, the 23.7x forward P/E demands patience. A pullback toward the trailing 16.5x multiple — which would require the stock to retreat toward C$36-38 — would re-establish a margin of safety that the current price doesn't offer. The gate is simple: if Manulife sustains mid-teens core EPS growth, the current multiple is defensible but not attractive. If growth normalizes to high single digits, the current price is rich.

The break condition for a downgrade from Hold to Sell would be a sustained reversal in the CSM growth trajectory or a material deterioration in the Asia NBV margin. Neither is visible right now. But the absence of a valuation gap means the risk-reward has shifted from asymmetric to balanced — and for a retirement portfolio, that matters.